The Role of Biosimilars in the Growth of Specialty Pharmacy

One of the hottest topics trending in specialty pharmacy is the emergence of biosimilars. In theory, biosimilars offer an opportunity to reduce medication spend for patients, payers, and pharmacies. 
To date, however, the acceptance and utilization of biosimilar products has largely been lagging. In order to understand why biosimilar use has been slow to gain traction within the marketplace, one must understand some of the key differences between biosimilar substitution, and that of traditionally substituted generics for brand name medications.
Biosimilars are defined as a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and efficacy from the reference product.
Only minor differences in clinically inactive components are allowable in biosimilar products.  What makes these products very different from traditional medications are that the drugs themselves are far more complex. 
Typically, biologics are 200 to 1000 times the size of a small molecule drug, and they are manufactured in living cells. The products are then extracted and purified to make the commercially available product. 
Conversely, small molecule drugs are manufactured through chemical synthesis. During the formulation of biologics, protein structures are translated from DNA sequences in varying cellular environments. 
The types of cells used to produce a product, and the environment contained within the cells themselves during production, could potentially lead to slight variations in the final product itself. This is highly different from small molecule products, which are replicated to be chemically identical to a reference product.
The Biologics Price Competition and Innovation Act (BPCI Act), signed into law as part of the Affordable Care Act on March 23, 2010, paved the way for the accelerated approval of biosimilar products. Under the law, a biological product may be demonstrated as biosimilar if that data shows it is “highly similar” to an already approved biological product. 
Interchangeable biological products demonstrate biosimilarity to FDA-approved products and meet additional standards for interchangeability. In the case of an interchangeable product, pharmacists may substitute the generic product for the reference product without intervention of the prescriber. 

With such stringent and specific criteria required for the proper substitution of brand name biologic products, there will certainly be uncertainty on behalf of prescribers and pharmacists as products become commercially available.
Adding to the confusion is that each biosimilar may come to market with specific data on only a select set of information compared with the branded product. Therefore, some biosimilars will be approved for all of the indications that the reference product is approved for, while others will only be approved for the indications that they were specifically tested for in clinical trials. 
As more biosimilars become available in the US marketplace, pharmacists will need to work closely with prescribers to determine which patients are appropriate to begin therapy with a biosimilar, which patients are eligible to transition to biosimilars who are currently stable on branded drugs, and which products should be automatically substituted by pharmacists with no prescriber intervention.
Adding additional complexity to the use of biosimilar products is how prescribers will be required to write prescriptions for them. The FDA has proposed that all prescriptions for biosimilars include a suffix that follows the proper name of the product. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

I learned myriad life and professional lessons from my travels.
ECRM’s innovative event brought together leaders from across specialty pharmacy.
WellDyneRx created an innovative program that controls costs and improves outcomes for patients with diabetes, according to a session presented at APhA2018.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.